Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE EUROPEAN MYOCARDIAL INFARCT AMIODARONE TRIAL (EMIAT)
Autore:
CAMM AJ; JULIAN D; JANSE G; MUNOZ A; SCHWARTZ P; SIMON P; FRANGIN G;
Indirizzi:
ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,CRANMER TERRACE LONDON SW17 0RE ENGLAND BRITISH HEART FDN LONDON ENGLAND UNIV AMSTERDAM,ACAD MED CTR 1105 AZ AMSTERDAM NETHERLANDS OSPED MAGGIORE MILANO MILAN ITALY SANOFI RECH PARIS FRANCE SANOFI RECH MONTPELLIER FRANCE
Titolo Testata:
The American journal of cardiology
fascicolo: 16, volume: 72, anno: 1993,
pagine: 60000095 - 60000098
SICI:
0002-9149(1993)72:16<60000095:TEMIAT>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
VENTRICULAR ARRHYTHMIAS; ANTIARRHYTHMIC THERAPY; MORTALITY; TACHYCARDIA; SURVIVORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
13
Recensione:
Indirizzi per estratti:
Citazione:
A.J. Camm et al., "THE EUROPEAN MYOCARDIAL INFARCT AMIODARONE TRIAL (EMIAT)", The American journal of cardiology, 72(16), 1993, pp. 60000095-60000098

Abstract

The objective of the European Myocardial Infarct Amiodarone Trial (EMIAT) is to assess the efficacy of amiodarone on mortality of patients with depressed left ventricular (LV) function following myocardial infarction (MI). The rationale for the trial is as follows: patients withpoor LV function after acute MI have a high sudden cardiac death (SCD) mortality; amiodarone is a successful prophylactic therapy against SCD in patients with ventricular arrhythmias; a number of small studies(Canadian Amiodarone Myocardial Infarction Arrththmia Trial [CAMIAT] pilot study, Basel Antiarrhythmia Study & Infarct Survival [BASIS], and the Polish Amiodarone Trial [PAT] of prophylactic amiodarone post AMI have shown a beneficial response attributable to amiodarone. Patients are enrolled between 5 and 21 days after acute MI if LV ejection fraction (assessed by multiple-gated image acquisition nuclear angiography) is less-than-or-equal-to 40%. The study group is stratified according to ejection fraction (stratum 1,31-40%; stratum 2, < 31%). Amiodarone or placebo treatment (blind, randomized) is initiated prior to the discharge of the patient from the hospital and each patient is followed up for the duration of the study, at least 1 year. Recruitment beganon November 30, 1990, and will continue for 4 years; < 700 patients are enrolled from > 60 centers (13 countries). The total study mortality (10% at 500 days) and the differential mortality of both strata are as anticipated. Side effects have been infrequent and very few patients have been withdrawn from the study. Trial conclusion is forecast forOctober 1995.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/07/20 alle ore 06:18:16